The use of short courses of physiological or pharmacological doses of estradiol to induce apoptosis in breast cancer cells with a hypersensitive ER in women whose tumours are resistant to multiple types of endocrine therapy including AIs has been suggested based upon preclinical models (96,97). The gene discussed is ESR1; the disease is breast carcinoma.